Cargando…

Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer

PURPOSE: The effects of chemotherapy dose intensity on survival in patients with advanced non-small-cell lung cancer (NSCLC) are poorly understood. We retrospectively analyzed dose delays/reduction, relative dose intensity (RDI), and the association between chemotherapy intensity and survival in adv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crawford, Jeffrey, Denduluri, Neelima, Patt, Debra, Jiao, Xiaolong, Morrow, Phuong Khanh, Garcia, Jacob, Barron, Richard, Lyman, Gary H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954126/ https://www.ncbi.nlm.nih.gov/pubmed/31172284 http://dx.doi.org/10.1007/s00520-019-04875-1

Ejemplares similares

The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study
por: Culakova, Eva, et al.
Publicado: (2015)

Assessing patients’ risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?
por: Lyman, Gary H, et al.
Publicado: (2015)

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim
por: Dale, David C., et al.
Publicado: (2017)

Examining Cardiotoxicity With HER2 Therapies
por: Denduluri, Neelima
Publicado: (2020)

The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: a multicentered retrospective analysis
por: Breadner, Daniel, et al.
Publicado: (2022)

Dose intensity in cancer chemotherapy.
por: Dodwell, D. J., et al.
Publicado: (1990)

Association of radiation dose intensity with overall survival in patients with distant metastases
por: Kao, Johnny, et al.
Publicado: (2021)

Intensive Chemotherapy Is Associated With Poor Overall Survival in Autoimmune Disease-associated Myeloid Malignancies
por: Richardson, Simon E., et al.
Publicado: (2018)

Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta‐Analysis
por: Nielson, Carrie M., et al.
Publicado: (2021)

Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study
por: Culakova, Eva, et al.
Publicado: (2014)

Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy
por: Karol, Seth E., et al.
Publicado: (2021)

Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2005)

NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim
por: Kirshner, Jeffrey J., et al.
Publicado: (2017)

Management of chemotherapy dose intensity for metastatic colorectal cancer
por: Chu, Xuelei, et al.
Publicado: (2022)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Möhring, Christian, et al.
Publicado: (2021)

The impact of increasing dose on overall survival in prostate cancer
por: Hall, Matthew D., et al.
Publicado: (2015)

Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer
por: Liu, Liya, et al.
Publicado: (2015)

High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer.
por: Ferguson, J. E., et al.
Publicado: (1993)

HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes
por: Robert, Nicholas J., et al.
Publicado: (2017)

Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era
por: Lyman, Gary H., et al.
Publicado: (2021)

Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma
por: Canton, Clémence, et al.
Publicado: (2022)

Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance Biomarkers
por: Barrón-Gallardo, Carlos A, et al.
Publicado: (2022)

Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
por: Morrow, Phuong Khanh H, et al.
Publicado: (2009)

Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
por: Denduluri, Neelima, et al.
Publicado: (2022)

The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma—including the analysis of clinicopathological factors influencing relative dose intensity
por: Yabusaki, Norimitsu, et al.
Publicado: (2016)

Correction to: Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma
Publicado: (2022)

Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
por: Grande, Enrique, et al.
Publicado: (2023)

C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib
por: Hayashi, Tsuguru, et al.
Publicado: (2020)

Impact of relative dose intensity in gemcitabine–cisplatin chemotherapy for metastatic urothelial carcinoma
por: Kohei, Naoki, et al.
Publicado: (2018)

Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma
por: Rožman, Samo, et al.
Publicado: (2022)

Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study
por: Marschner, Norbert, et al.
Publicado: (2015)

Chemotherapy Use at the End of Life in Uganda
por: Low, Daniel, et al.
Publicado: (2017)

When Stars Do Not Align: Overall Hospital Quality Star Ratings and the Volume-Outcome Association
por: Fontana, Mark Alan, et al.
Publicado: (2019)

The Appropriate First-Line Chemotherapy Regimen for Incurable Pancreatic Cancer in Clinical Practice: A Consideration of Patients' Overall Survival and Quality of Life
por: Murakawa, Yasuko, et al.
Publicado: (2021)

Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer
por: PETTY, W. JEFFREY, et al.
Publicado: (2013)

Dose Delays, Dose Reductions, and Relative Total Dose Intensity in Patients With Advanced Cancer Who Exercised During Neoadjuvant Chemotherapy Treatment
por: Wonders, Karen Y., et al.
Publicado: (2023)

The Association Between Radiation Therapy Dose and Overall Survival in Patients With Intracranial Infiltrative Low-Grade Glioma Treated With Concurrent and/or Adjuvant Chemotherapy
por: Prabhu, Roshan S., et al.
Publicado: (2020)

Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?
por: LeVasseur, N, et al.
Publicado: (2017)

Marginal structural models with dose-delay joint-exposure for assessing variations to chemotherapy intensity
por: Lancia, Carlo, et al.
Publicado: (2018)

Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
por: Schwenkglenks, Matthias, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_u8gpqrmais7401v9bbmmkirlo3